HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS

Clinical trials for HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS explained in plain language.

Never miss a new study

Get alerted when new HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear

Sign up with your email to follow new studies for HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New 'Living Drug' trial offers hope for lymphoma patients out of options

Disease control Recruiting now

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…

Matched conditions: HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS

Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control

Last updated Mar 12, 2026 13:52 UTC

HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS

Get alerted when new HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear

New 'Living Drug' trial offers hope for lymphoma patients out of options